Since mitotic exit by slippage has been found as typical response of TP53-mutant cancer cells to resist drug-induced mitotic cell death and blocking mitotic exit has already shown to successfully reduce tumor growth in paclitaxel-treated ovarian cancer models [54], we speculate that additional blocking of mitotic exit by APC/C inhibitor proTAME could have enhanced the anti-tumor effects of PARP1i. Here, TP53 is linked to cancer.